Literature DB >> 9062483

Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors.

H J Balks1, J J Holst, A von zur Mühlen, G Brabant.   

Abstract

The mechanisms involved in the rapid glucagon-like peptide-1 (GLP-1) release following glucose ingestion are poorly defined. Besides a direct intestinal stimulation of L cells, humoral and neuronal mechanisms have been discussed. We investigated the temporal pattern of GLP-1 release in five healthy men (aged 27.8 +/- 3.6 yr, body mass index, 23.4 +/- 1.2 kg/m2) after an overnight fast for 60 min under basal conditions and for 60 min after an oral glucose load (OGL; 100 g) in both the presence and absence of atropine (80 ng/kg min, iv). Blood was sampled every 2 min, and data were evaluated for the temporal pattern of GLP-1 secretion by several computer-assisted programs (deconvolution, Pulsar analysis, and Fourier transformation). With all methods a pulsatile pattern of plasma GLP-1 levels with a frequency of five to seven per h was detected; this remained unchanged in the different metabolic states and during atropine treatment. Glucose and GLP-1 plasma levels showed a parallel increase after OGL (OGL without atropine = control: 8.4 +/- 2.9 and 7.9 +/- 3.0 min, respectively). Atropine infusion delayed this increase significantly (16.8 +/- 8.07 and 17.4 +/- 6.61 min, respectively; P < 0.02). In contrast to plasma glucose concentrations (82.7 +/- 0.3% of control; P < 0.05), atropine infusion reduced the integrated GLP-1 pulse amplitude to 56.0 +/- 11.3% of the control levels (P < 0.05). In conclusion, GLP-1 is secreted in a pulsatile manner with a frequency comparable to that of pancreatic hormones. Mean GLP-1 plasma concentrations increase after OGL due to augmented GLP-1 pulse amplitudes but not frequency. The differential effect of atropine on glucose and GLP-1 plasma levels suggest a direct cholinergic muscarinic control of L cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062483     DOI: 10.1210/jcem.82.3.3816

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

3.  A low GLP-1 response among patients treated for acute organophosphate and carbamate poisoning: a comparative cross-sectional study from an agrarian region of Sri Lanka.

Authors:  Devarajan Rathish; Indika Senavirathna; Channa Jayasumana; Suneth Agampodi; Sisira Siribaddana
Journal:  Environ Sci Pollut Res Int       Date:  2018-11-29       Impact factor: 4.223

Review 4.  Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.

Authors:  Charlotte X Dong; Patricia L Brubaker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

5.  Uncoupling protein 2 regulates glucagon-like peptide-1 secretion in L-cells.

Authors:  Yan Chen; Zheng-Yang Li; Yan Yang; Hong-Jie Zhang
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 8.  Effects of GLP-1 on appetite and weight.

Authors:  Meera Shah; Adrian Vella
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 9.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

10.  Bariatric surgery for extreme adolescent obesity: indications, outcomes, and physiologic effects on the gut-brain axis.

Authors:  Stavra A Xanthakos
Journal:  Pathophysiology       Date:  2008-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.